This is a routine post-annual-meeting filing with no new financial or strategic information. The additional 1.5M shares for the incentive plan are a standard administrative matter. Monitor the next quarterly report for any operational or pipeline updates that could move the stock.
Price Chart
Executive Summary
Dare Bioscience's 2026 annual meeting results were reported via 8-K, with all 8 proposals passing, including director elections, ratification of auditors, advisory say-on-pay, and approval of a 1.5 million share increase to the 2022 Stock Incentive Plan. The filing is a routine post-meeting report with no financial data or unexpected corporate events.
Key Facts
- Stockholders approved an amendment to the 2022 Stock Incentive Plan adding 1,500,000 shares available for issuance (total shares reserved increased to 2,883,333).
- Class III directors Gregory W. Matz and Sabrina Martucci Johnson were elected to terms ending at the 2029 annual meeting.
- Stockholders ratified Haskell & White LLP as independent auditor for FY2026.
- An advisory vote on executive compensation was approved, with the board opting for an annual say-on-pay frequency.
- Stockholders approved the potential future issuance of shares under the existing Lincoln Park Capital equity line, and the adjournment proposals were not needed.
- No officer departures, financial results, or material corporate changes were reported.
Financial Impact
No financial figures reported in this filing; the stock plan amendment allows for future dilution but no immediate capital event.
Risk Factors
- Potential future dilution from the expanded stock plan if large equity grants are issued.
- The company continues engaging a proxy solicitor (Okapi Partners) ahead of the meeting, hinting at contested voting dynamics at the micro-cap level.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001401914-26-000032 |
| Exhibit: ex101_amendmentno22022sip.htm | 0001401914-26-000032 |
| Document: 0001401914-26-000032-index-headers.html | 0001401914-26-000032 |
| Document: 0001401914-26-000032-index.html | 0001401914-26-000032 |
| Document: 0001401914-26-000032.txt | 0001401914-26-000032 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | DEF 14A | $0.7900 $0.7720 | ▲ +2.28% | ▲ +1.86% | $0.6467 (+18.14%) |
Oct 1, 2026 25d ago | 8-K | $0.8510 $0.8428 | ▼ −0.96% | ▼ −1.70% | $0.6467 (−24.01%) |
Sep 9, 2026 6w ago | 8-K | $0.7166 $0.7051 | ▼ −1.60% | ▼ −1.01% | $0.6467 (−9.75%) |
Sep 4, 2026 7w ago | EFFECT | $0.7210 $0.7130 | ▲ +1.11% | ▲ +0.56% | $0.6467 (+10.31%) |
Aug 17, 2026 10w ago | 8-K | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 17, 2026 10w ago | 424B5 | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 13, 2026 10w ago | 8-K | $0.9300 $0.8102 | ▼ −12.88% | ▼ −12.41% | $0.6467 (−30.46%) |
Aug 6, 2026 11w ago | Press Release | $1.33 $1.40 | ▲ +5.26% | ▲ +4.65% | $0.6467 (−51.38%) |
Jul 24, 2026 13w ago | 8-K | $1.28 $1.32 | ▲ +3.13% | ▲ +3.10% | $0.6467 (−49.48%) |
Jul 13, 2026 15w ago | 8-K | $2.09 $2.07 | ▼ −0.96% | ▼ −1.31% | $0.6467 (−69.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers